A Study of 18F-AV-45 in Healthy Volunteers

Avid Pharmaceuticals

Status and phase: Completed; Phase 1

Conditions: Alzheimer Disease

Treatments: Drug: florbetapir F 18

Study type: Interventional

Funder types: Industry

Identifiers

NCT01564706

18F-AV-45-A02

Details and patient eligibility

About

This study will determine how florbetapir F 18 (18F-AV-45) radioactivity is distributed throughout the body.

Enrollment: 9 patients

Sex: All

Ages: 18 to 85 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Able to lie still on the imaging table for periods up to 1 hour

Exclusion criteria

• Radiation exposure for experimental purposes within the last year
• Claustrophobic or otherwise unable to tolerate the imaging procedure
• Medical condition or surgical history that would confound evaluation
• Current clinically significant cardiovascular disease
• Received an investigational medication within the last 30 days

Trial design

Primary purpose: Diagnostic

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

9 participants in 1 patient group

Healthy Volunteers

Experimental group

Description:

Healthy male or female subjects, between 18 and 85 years of age.

Treatment:

Drug: florbetapir F 18